Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart dosing could make MDR-TB treatment safer

NCT ID NCT07477119

Recruiting now Disease control Sponsor: Marco Schiuma Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adjusting the dose of the antibiotic linezolid based on regular blood tests can reduce harmful side effects in people being treated for multidrug-resistant tuberculosis (MDR-TB). The trial will enroll 150 patients in Guinea who are on a standard 6-month regimen called BPaL. Half will receive standard linezolid dosing, while the other half will have their dose adjusted to keep blood levels in a safe range. The goal is to see if personalized dosing lowers the risk of nerve damage and other serious side effects without reducing treatment success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
linezolid
What this could lead to
If successful, this approach could make MDR-TB treatment safer by reducing serious side effects like nerve damage and bone marrow suppression.
What could go wrong
This is a Phase 4 study in one country (Guinea) with 150 participants. The benefit of dose personalization is not yet proven, and the method may be hard to implement in low-resource settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LINEZOLID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Drug-Related Side Effects and Adverse Reactions multidrug-resistant tuberculosis peripheral nervous system disorder tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LINEZOLID THERAPEUTIC DRUG MONITORING (TDM) TUBERCULOSIS MULTI DRUG RESISTANT ACTIVE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre de Santé de Tombolia

    RECRUITING

    Conakry, Guinea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.